• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Realbotix Corp. Provides Corporate Structure and Operations Update

    7/22/26 11:25:00 AM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ONCO alert in real time by email

    Commercial robotics and online consumer businesses maintain separate management, personnel, operations and product strategies

    Realbotix Corp. (TSXV:XBOT) (Frankfurt: 76M0.F) (OTC:XBOTF) ("Realbotix" or the "Company") provides an overview of its corporate and operating structure.

    Realbotix Corp. is a holding company with two separately operated businesses: Realbotix LLC, which focuses on AI-powered humanoid robotics for commercial service sector applications, and Intima LLC, which focuses on direct-to-consumer products. Realbotix LLC and Intima LLC have different product offerings with no crossover. As a holding company, Realbotix Corp. does not in itself have business operations but is responsible for managing capital markets, shareholders, listing requirements and accounting needs. The two subsidiaries maintain their own management, personnel, payroll, facilities, manufacturing operations, product development, and market strategies.

    "Realbotix LLC, our commercial robotics team, is solely focused on developing AI-powered humanoid systems that support practical applications in education, healthcare, hospitality, entertainment, customer service and wellness," said Andrew Kiguel, CEO of Realbotix. "Realbotix LLC and Intima LLC are separate legal entities with different leadership, staff, and products. This update is intended to give customers, partners and shareholders a clear understanding of how each business operates."

    Realbotix LLC: Commercial Robotics and Embodied AI

    Realbotix LLC is a commercial and enterprise robotics business. It develops and manufactures AI-powered humanoid robots and embodied AI systems for applications including education, healthcare, hospitality, entertainment, customer service, and wellness.

    Realbotix LLC operates through its own leadership and dedicated team. Andrew Kiguel leads its operations, and the business has approximately 25 employees, all recruited in the last two years, focused exclusively on commercial robotics and AI applications. Its team operates from its own facility using dedicated manufacturing and product development processes.

    Realbotix LLC does not design, manufacture or sell adult products. No Intima LLC or RealDoll employees, contractors, products, inventory, blueprints or technology are involved in Realbotix LLC’s design, engineering, manufacturing, deployment or customer support. All education, healthcare, wellness, and enterprise initiatives are conducted exclusively through Realbotix LLC.

    Under a transaction announced February 10, 2026, with Onconetix, Inc. (NASDAQ:ONCO), Onconetix would merge with Realbotix LLC through an all-stock share exchange. The proposed transaction is subject to customary closing conditions and required approvals and is expected to close in the second half of 2026. The intent of this transaction is that Realbotix LLC and Intima LLC will each operate as their own public company listing and lead to each having independent ownership in the public markets. Further details can be found in a press release dated May 19, 2026.

    Intima LLC: Online Direct-to-Consumer Business

    Intima LLC is an online direct-to-consumer business that manufactures products and AI for the adult wellness and companionship market. Intima LLC is led by Sue Ennis, who determines the strategy and direction of the business, and manages day-to-day operations. Intima maintains its own employees, facility, manufacturing operations, and product portfolio, including an 86% ownership of RealDoll, which has existed for over 25 years.

    Separate Operations and Customer Engagement

    Realbotix LLC and Intima LLC are different legal entities that are independently operated. The two entities do not share employees, products, inventory, manufacturing resources, or technology.

    Customers and partners engaging with Realbotix LLC work exclusively with its commercial robotics team and products. Realbotix LLC is focused on advancing humanoid robotics and embodied AI systems designed to support human interaction in healthcare, education, hospitality, and other service sector applications.

    Inaccurate Media Reporting

    Realbotix has retained legal counsel to address some recent inaccurate and misleading media reports regarding our company and its operations. The Company will pursue all available legal remedies, including prosecution where appropriate, against any media outlet or individual that continues to publish false or defamatory information about Realbotix Corp, Realbotix LLC, Intima, or any of its affiliates and subsidiaries.

    "There have been several media outlets reporting false information that misrepresent our mission, technology, and products, causing unnecessary confusion," said Andrew Kiguel, CEO of Realbotix. "Realbotix and its subsidiaries remain focused on delivering innovative, ethical, and compliant robotic and AI solutions, and we encourage media outlets to contact us directly for verified information. We value responsible journalism and invite legitimate inquiries as we continue to advance our technology."

    About Realbotix Corp.

    Realbotix Corp. is a U.S. based holding company that focuses on humanoid robots and embodied AI systems designed for natural human interaction. Manufactured in the United States, Realbotix’s patented technologies enable lifelike facial expressions, fluid movement, vision systems, and advanced social engagement. The Company’s platforms are developed for applications in healthcare, education, service industries, and consumer markets. For more information visit www.realbotix.ai.

    Stay updated by joining our online communities on Twitter, LinkedIn, and YouTube.

    Forward-Looking Statements

    This news release contains forward-looking statements and information within the meaning of applicable securities laws, including management’s objectives, strategies, beliefs, and intentions. Forward-looking statements are often, but not always, identified by words such as "may," "will," "plan," "expect," "anticipate," "estimate," "intend," "believe," or similar expressions referring to future events or results.

    These forward-looking statements are based on management’s current opinions and expectations and are subject to known and unknown risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from those expressed or implied by such statements.

    Readers are cautioned not to place undue reliance on forward-looking statements. Although management believes that the expectations reflected in these forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct.

    All forward-looking statements are subject to the risks and uncertainties detailed in the Company’s continuous disclosure filings available at www.sedarplus.ca. The Company assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable law.

    Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20260722562302/en/

    Andrew Kiguel, CEO

    Contact@realbotix.com

    media@realbotix.com

    sales@realbotix.com

    Telephone: 647-578-7490

    Get the next $ONCO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ONCO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ONCO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Realbotix Corp. Provides Corporate Structure and Operations Update

    Commercial robotics and online consumer businesses maintain separate management, personnel, operations and product strategies Realbotix Corp. (TSXV:XBOT) (Frankfurt: 76M0.F) (OTC:XBOTF) ("Realbotix" or the "Company") provides an overview of its corporate and operating structure. Realbotix Corp. is a holding company with two separately operated businesses: Realbotix LLC, which focuses on AI-powered humanoid robotics for commercial service sector applications, and Intima LLC, which focuses on direct-to-consumer products. Realbotix LLC and Intima LLC have different product offerings with no crossover. As a holding company, Realbotix Corp. does not in itself have business operations but is

    7/22/26 11:25:00 AM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Onconetix Highlights Realbotix Partnership with Bloom Services to Launch UK Pilot Using Humanoid Robots to Combat Elderly Social Isolation

    Realbotix Robots and AI to Deploy in Evidence-Based Pilot Designed to Improve Wellbeing and Address Loneliness Among Older Adults in UK Care Settings; Realbotix Becomes Accredited Supplier on Bloom’s Public Sector Marketplace; Onconetix Recently Entered into a Definitive Agreement to Acquire Realbotix LLC, a Subsidiary of Realbotix Corp. CINCINNATI, Ohio, July 07, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:ONCO) ("Onconetix" or the "Company") is providing the following summary of a press release issued by Realbotix Corp., parent of Realbotix LLC ("Realbotix"), the target of Onconetix’s previously announced pending acquisition. Realbotix has announced a partnership with Bloom Procu

    7/7/26 9:00:00 AM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Onconetix Highlights Realbotix’s Launch of Humanoid Robot and AI Teachers Assistant Pilot Program in New York State School District

    Salamanca City Central School District on Seneca Nation Reservation to Deploy Optio and Realbotix M-Series Humanoid Robot; Pilot to Expand to Approximately 500 High School Students in Fall 2026; Onconetix Recently Entered into a Definitive Agreement to Acquire Realbotix LLC, a Subsidiary of Realbotix Corp. CINCINNATI, Ohio, June 24, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:ONCO) ("Onconetix" or the "Company") is providing the following summary of a press release issued by Realbotix Corp., parent of Realbotix LLC ("Realbotix"), the target of Onconetix’s previously announced pending acquisition. Realbotix has launched Optio, its AI-powered teacher’s assistant, in a pilot program a

    6/24/26 8:30:00 AM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ONCO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Hrt Financial Lp

    4 - Onconetix, Inc. (0001782107) (Issuer)

    4/22/26 2:59:05 PM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Hrt Financial Lp

    4 - Onconetix, Inc. (0001782107) (Issuer)

    4/21/26 3:41:33 PM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Hrt Financial Lp

    4 - Onconetix, Inc. (0001782107) (Issuer)

    4/16/26 2:30:24 PM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ONCO
    SEC Filings

    View All

    SEC Form 425 filed by Onconetix Inc.

    425 - Onconetix, Inc. (0001782107) (Subject)

    7/7/26 9:01:30 AM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 425 filed by Onconetix Inc.

    425 - Onconetix, Inc. (0001782107) (Subject)

    6/24/26 8:31:31 AM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B3 filed by Onconetix Inc.

    424B3 - Onconetix, Inc. (0001782107) (Filer)

    6/17/26 11:24:43 AM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ONCO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Onconetix Inc.

    SC 13G - Onconetix, Inc. (0001782107) (Subject)

    11/14/24 11:19:35 AM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Onconetix Inc.

    SC 13D - Onconetix, Inc. (0001782107) (Subject)

    10/1/24 4:35:03 PM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Onconetix Inc.

    SC 13D - Onconetix, Inc. (0001782107) (Subject)

    10/1/24 4:35:03 PM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ONCO
    Leadership Updates

    Live Leadership Updates

    View All

    $ONCO
    Financials

    Live finance-specific insights

    View All

    Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board

    Virometix AG, a privately held Swiss biotechnology company developing a new generation of fully synthetic vaccines to generate targeted and protective immune responses against infectious diseases and cancer today announces the appointment of Christina Ackermann as Chairwoman and Tim Ramdeen as a new member of its Board of Directors. Ms. Ackermann brings over 27 years of legal and management experience within the healthcare industries. Mr. Ramdeen has nearly a decade of experience in private equity, hedge fund investing, and capital markets. Christina Ackermann and Tim Ramdeen have led clinical and commercial companies through product development, growth, and commercialization while raising

    10/8/24 5:00:00 AM ET
    $ENTO
    $OCS
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Realbotix Reports Financial Results for Q2-2026

    Realbotix Corp. (TSXV:XBOT) (Frankfurt: 76M0.F) (OTC:XBOTF) ("Realbotix" or the "Company"), a leading developer of humanoid robots and AI systems designed for human interaction across enterprise and consumer environments, reports its interim financial results for the three and six months ended March 31, 2026 ("Q2-2026"). All dollar figures are reported in United States dollars ("USD"), unless otherwise stated. Q2-2026 Financial and Operating Highlights For the three and six months ended March 31, 2026, the Company generated revenue of $225,000 and $578,000, respectively, compared to $727,000 and $1,543,000 for the corresponding periods in the prior fiscal year. The decline in revenue i

    5/29/26 7:30:00 AM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care